Associations between \textit{XPD} Asp312Asn Polymorphism and Risk of Head and Neck Cancer: A Meta-Analysis Based on 7,122 Subjects

Yuan Yuan Hu\textsuperscript{1}, Hua Yuan\textsuperscript{2}, Guang Bing Jiang\textsuperscript{3}, Ning Chen\textsuperscript{2}, Li Wen\textsuperscript{4}, Wei Dong Leng\textsuperscript{1}, Xian Tao Zeng\textsuperscript{1}, Yu Ming Niu\textsuperscript{1,2,*}

\textsuperscript{1}Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China, \textsuperscript{2}Institute of Dental Research, Nanjing Medical University, Nanjing, People’s Republic of China, \textsuperscript{3}Department of Radiology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China, \textsuperscript{4}Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China

\section*{Abstract}

\textbf{Background:} To investigate the association between XPD Asp312Asn polymorphism and head and neck cancer risk through this meta-analysis.

\textbf{Methods:} We performed a meta-analysis of 9 published case-control studies including 2,670 patients with head and neck cancer and 4,452 controls. An odds ratio (OR) with a 95\% confidence interval (CI) was applied to assess the association between XPD Asp312Asn polymorphism and head and neck cancer risk.

\textbf{Results:} Overall, no significant association between XPD Asp312Asn polymorphism and head and neck cancer risk was found in this meta-analysis (Asn/Asn vs. Asp/Asp: OR = 0.95, 95\%CI = 0.80–1.13, \(P = 0.550\), \(I^2 = 0.126\); Asn/Asn vs. Asp/Asp: OR = 1.11, 95\%CI = 0.99–1.24, \(P = 0.056\), \(I^2 = 0.663\); Asn/Asn+Asp/Asn vs. Asp/Asp: OR = 1.07, 95\%CI = 0.97–1.19, \(P = 0.189\), \(I^2 = 0.627\)); Asn/Asn vs. Asp/Asp+Asp/Asn: OR = 0.87, 95\%CI = 0.68–1.10, \(P = 0.243\), \(I^2 = 0.089\)). In the subgroup analysis by HWE, ethnicity, and study design, there was still no significant association detected in all genetic models.

\textbf{Conclusions:} This meta-analysis demonstrates that XPD Asp312Asn polymorphism may not be a risk factor for developing head and neck cancer.

\section*{Introduction}

Head and neck cancers (HNC) constitute about 5\% of all cancers recorded in the US, and the incidence is increasing in most developed and developing countries. These cancers have been estimated to be about six times more common among smokers than non-smokers and are most common in males over 50 years old [1,2], which increases to about 15 times if the smokers are also heavy drinkers [3,4]. Although many measures had been done to improve the diagnosis and treatments, the prognosis was still poor.

Many environmental factors, such as radiation, diet, smoking, and endogenous or exogenous estrogens, are associated with DNA damage. Unrepaired or misrepaired DNA results in gene mutations, chromosomal alterations, and genomic instability. Several studies have suggested that genes involved in DNA repair play a crucial role in protecting against mutations. Patients with certain cancers have reduced capacities for DNA repair. Similarly, the enzymes of the nucleotide excision repair (NER) pathway have been implicated in cancer. Associations between polymorphisms in several DNA repair genes and the risks of several types of cancer have been extensively examined. Many epidemiologic cancer studies have focused on single nucleotide polymorphisms (SNPs) in genes in the NER pathway such as \textit{XPD}, \textit{ERCC1}, and \textit{XPC} [5]. The \textit{XPD} protein is a DNA helicase and is an essential part of the TFIIH transcription factor complex. Some studies have suggested that \textit{XPD} polymorphisms may be associated with reduced DNA repair because of a possible reduction in helicase activity [6,7]. One of the common \textit{XPD} polymorphisms in the coding regions is Asp312Asn in exon 10. The functional significance is not yet completely clear, although the amino acid mutations in exon 10 give rise to a loss of an acidic residue and a complete change in the electronic configuration of the amino acid [8,9].

The first study on the relationship between HNC and \textit{XPD} Asp312Asn polymorphism was conducted by Sturgis et al. [10].
They found a borderline significant association between XPD Asp312Asn polymorphism and HNC. Since then, a lot of studies have confirmed or refuted this finding [11–19]. In 2010, a recent meta-analysis was conducted by Flores-Obando et al. [19] demonstrating that increased HNC risk is associated with XPD Asp312Asn polymorphism. Worthy of note, that meta-analysis included five studies were conducted in Caucasian populations and one in an Asian population [10–15]. Today, nine case-control studies on XPD Asp312Asn polymorphism and HNC risk have been published. A comprehensive meta-analysis is needed to provide an updated approach on the overall relationship. Subgroup analyses were also performed on Caucasian and Asian populations to investigate ethnicity-specific effects.

Methods

Search strategy

The PubMed database was searched with terms “head and neck cancer”, “oral cancer”, “oropharyngeal cancer”, “laryngeal cancer”, “pharyngeal cancer”, “XPD”, “excision repair cross-complementing group 2”, “polymorphism”, and the combined phrases for all genetic studies on the relationship between XPD polymorphism and HNC risk from 2000, when the first study of the association between XPD Asp312Asn polymorphism and HNC risk was reported, to October 2011. We also used the “Related Articles” option in PubMed to identify additional studies on the same topic. Reference lists in retrieved articles were also screened for. All selected studies complied with the following three criteria: (a) case–control study on the XPD Asp312Asn polymorphism and HNC risk; (b) sufficient published data for estimating the odds ratio (OR) with 95% confidence interval (CI); (c) For multiple publications reporting on the same data or overlapping data, the largest or most recent publication was selected [20].

Data extraction

Two investigators (Hu and Yuan) independently extracted the following data from each included publication: the first author’s name, publication data, sources of controls, racial descent of the study population (categorized as either Asian or Caucasian), genotyping method, number of cases, cases and controls with the association between XPD Asp312Asn polymorphism and HNC risk from 2000, when the first study of the association between XPD Asp312Asn polymorphism and HNC risk was published. A comprehensive meta-analysis is needed to provide an updated approach on the overall relationship. Subgroup analyses were also performed on Caucasian and Asian populations to investigate ethnicity-specific effects.

Statistical analysis

Crude ORs with 95% CIs were computed to assess the strength of the correlation between the XPD Asp312Asn polymorphism and HNC risk. The pooled ORs were performed for codominant model (Asn/Asn vs. Asp/Asp,Asp/Asn vs. Asp/Asp), dominant model (Asn/Asn vs. Asp/Asp,Asp/Asn vs. Asp/Asp), and recessive model (Asn/Asn vs. Asp/Asp,Asp/Asn vs. Asp/Asp), respectively. In the subgroup analysis, statistical analysis was conducted on Asian and Caucasians. Heterogeneity assumption was assessed by the chi-square based Q-test [21]. The pooled OR estimation of each study was calculated by the fixed-effects model (the Mantel–Haenszel method) when P=0.10. Otherwise, the random-effects model (the DerSimonian and Laird method) was used [22]. The potential publication bias was estimated by the modified Egger’s linear regression test, which proposed by Harbord et al. [23]. Statistical analysis was performed using STATA version 11.0 (Stata Corporation, College Station, TX, USA) and Review Manage (v.4.2; Oxford, England), using two-sided P-values, with P<0.05 considered statistically significant.

Results

Study characteristic

This meta-analysis is guided by the PRISMA statement (Checklist S1). A total of 49 relevant studies were identified (Figure 1). After carefully review, nine eligible case-control studies on the relationship between XPD Asp312Asn polymorphism and HNC risk were included in this meta-analysis [10–18]. Table 1 presents the main characteristics of these studies. Seven studies involved Caucasian populations [10–12,14,16,18], whereas two studies involved Asians [13,17]. Diverse genotyping methods were used, including PCR-SSCP, PCR-RFLP, Taqman, Real-time PCR and SEB PCR. All studies indicated that the genotypic distribution of the controls was consistent with HWE except one [17].

Meta-analysis

The main results of this meta-analysis and the heterogeneity test are shown in Table 2. Overall, no significant relationship was observed between XPD Asp312Asn polymorphism and HNC risk in the total populations (for Asn/Asn vs. Asp/Asp: OR = 0.95, 95%CI = 0.80–1.13, P = 0.550, Pheterogeneity = 0.126; Asp/Asn vs. Asp/Asp: OR = 1.11, 95%CI = 0.99–1.24, P = 0.065, Pheterogeneity = 0.663; Asn/Asn+Asp/Asn vs. Asp/Asp: OR = 1.07, 95%CI = 0.97–1.19, P = 0.189, Pheterogeneity = 0.627; Asn/Asn vs. Asp/Asp+Asp/Asn: OR = 0.87, 95%CI = 0.68–1.10, P = 0.243, Pheterogeneity = 0.089). Similarly, in the succeeding analysis of HWE studies, no significant association was found between XPD Asp312Asn polymorphism and HNC risk.
HNC risk: For Asn/Asn vs. Asp/Asp; OR = 0.95, 95% CI = 0.80–1.14, \(P = 0.586\), \(P\) heterogeneity = 0.120; Asp/Asn vs. Asp/Asp: OR = 1.11, 95% CI = 0.99–1.24, \(P = 0.089\), \(P\) heterogeneity = 0.586; Asn/Asn+Asp/Asn vs. Asp/Asp: OR = 1.07, 95% CI = 0.96–1.19, \(P = 0.219\), \(P\) heterogeneity = 0.526; Asn/Asn vs. Asp/Asp+Asn: OR = 0.92, 95% CI = 0.69–1.11, \(P = 0.278\), \(P\) heterogeneity = 0.082). Finally, in the stratified analysis of ethnicity and study design, we also did not find any significant association between XPD Asp312Asn polymorphism and HNC.

Sensitivity analysis

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual dataset to the pooled ORs. The analysis results demonstrate a borderline increased risk after excluding the studies that in Asp/Asn vs. Asp/Asp model [14,16,18] (Figure 2). The other corresponding pooled ORs were not materially altered (data not shown), indicating that our results are statistically robust.

Publication bias

Funnel plot and modified Egger’s test were performed to estimate the publication bias of literature. The shapes of the funnel plots in all genetic models did not reveal any evidence of obvious asymmetry. Figure 3 shows the shapes of the funnel plots of codominant model (Asp/Asn vs. Asp/Asp), used in the studies for examining all populations. The result was further supported by analysis via modified Egger’s tests. No significant publication bias was found in this meta-analysis (\(P = 0.093\) for Asn/Asn vs. Asp/Asp; \(P = 0.370\) for Asp/Asn vs. Asp/Asp; \(P = 0.173\) for Asn/Asn+Asp/Asn vs. Asp/Asp; \(P = 0.213\) for Asn/Asn vs. Asp/Asp+Asn).

Discussion

Today, genetic susceptibility to cancer has attracted growing attention to the study of gene polymorphisms involved in tumorigenesis. The XPD gene has been mapped to chromosome 19q13.3 and it is composed of 23 exons. Germline mutations in the XPD gene can result in xeroderma pigmentosum and other diseases. The XPD protein is involved in transcription-coupled NER and is an integral member of the basal transcription factor BTF2/TFIIH complex.

The Asp to Asn change at position 312 of XPD changes the electronic configuration of amino acid and alters the interaction between XPD protein and its helicase activator [6]. Wolfe et al.

---

**Table 1.** Characteristics of case-control studies on XPD Asp312Asn polymorphism and HNC risk included in the meta-analysis.

| First author | Year | Race | Source of controls | Case | Control | Genotype distribution | Genotyping type | \(P\) for HWE |
|--------------|------|------|-------------------|------|---------|-----------------------|-----------------|--------------|
| Sturgis      | 2002 | Caucasian | Hospital-based | 313  | 313     | 123 165 25 142 135 36 | PCR-SSCP       | 0.650        |
| Matullo      | 2006 | Caucasian | Population-based | 82   | 1094    | 32 46 4 418 506 170  | TaqMan         | 0.411        |
| An           | 2007 | Caucasian | Hospital-based  | 829  | 854     | 330 395 104 370 386 98 | PCR-RFLP      | 0.860        |
| Harth        | 2008 | Caucasian | Hospital-based  | 311  | 298     | 113 158 40 101 145 52  | Real-time PCR  | 0.997        |
| Abbasi       | 2009 | Caucasian | Population-based | 246  | 644     | 93 119 34 258 304 82   | PCR-RFLP      | 0.606        |
| Jelonek      | 2010 | Caucasian | Hospital-based  | 29   | 58      | 10 14 5 14 36 8      | SBE PCR        | 0.052        |
| Ji           | 2010 | Asian  | Hospital-based   | 829  | 854     | 330 395 104 370 386 98 | Real-time PCR  | 0.606        |
| Gugatschka   | 2011 | Caucasian | Population-based | 291  | 462     | 116 133 42 171 208 83 | TaqMan         | 0.158        |

**Table 2.** Summary ORs and 95% CI of XPD Asp312Asn polymorphism and HNC risk.

| Source of controls | OR | 95% CI | \(P\) | \(I^2\) | OR | 95% CI | \(P\) | \(I^2\) | OR | 95% CI | \(P\) | \(I^2\) |
|-------------------|----|--------|------|-------|----|--------|------|-------|----|--------|------|-------|
| Total             | 0.95 | 0.80–1.13 | 0.550 | 0.126 | 1.11 | 0.99–1.24 | 0.065 | 0.663 | 1.07 | 0.97–1.19 | 0.189 | 0.627 | 0.87 | 0.68–1.10 | 0.243 | 0.089 |
| HWE               | 0.95 | 0.80–1.14 | 0.593 | 0.120 | 1.11 | 0.99–1.24 | 0.089 | 0.586 | 1.07 | 0.96–1.19 | 0.219 | 0.528 | 0.82 | 0.69–1.11 | 0.278 | 0.082 |
| Ethnicity         |     |         |      |       |     |         |      |       |     |         |      |       |     |         |      |       |
| Asian             | 1.20 | 0.73–2.00 | 0.470 | 0.213 | 1.14 | 0.87–1.50 | 0.345 | 0.649 | 1.14 | 0.88–1.48 | 0.328 | 0.951 | 1.16 | 0.71–1.89 | 0.546 | 0.216 |
| Caucasian         | 0.92 | 0.76–1.11 | 0.366 | 0.121 | 1.11 | 0.98–1.25 | 0.110 | 0.468 | 1.06 | 0.94–1.19 | 0.317 | 0.430 | 0.83 | 0.64–1.08 | 0.165 | 0.085 |
| Design            |     |         |      |       |     |         |      |       |     |         |      |       |     |         |      |       |
| Hospital based    | 1.01 | 0.81–1.25 | 0.938 | 0.296 | 1.14 | 1.00–1.31 | 0.052 | 0.468 | 1.12 | 0.98–1.27 | 0.092 | 0.543 | 0.95 | 0.78–1.16 | 0.631 | 0.224 |
| Population based  | 0.75 | 0.43–1.32 | 0.248 | 0.063 | 1.04 | 0.85–1.28 | 0.684 | 0.692 | 0.98 | 0.81–1.19 | 0.865 | 0.611 | 0.73 | 0.42–1.28 | 0.271 | 0.045 |

\({}^*\) Test for heterogeneity.

\(^1\) Estimates for random effects model.

doi:10.1371/journal.pone.0035220.t001

---

**Figure 1.** XPD Asp312Asn Polymorphism and HNC Risk. doi:10.1371/journal.pone.0035220.t002
demonstrated that the 312 codon polymorphisms significantly decrease the constitutive ERCC2 mRNA levels, especially in smokers [24]. Hou et al. reported that the XPD 312 variant allele may be associated with the reduced repair of aromatic DNA adducts [25]. Matullo et al. proposed that exposure to environmental carcinogens, such as polycyclic aromatic hydrocarbons (PAHs), also accelerate cancer development through the codon 312 variant allele of XPD [26].

Correlations between the polymorphisms and some cancer risks have been studied, but the results remain controversial. The XPD Asp312Asn polymorphism has been shown to increase the risk of bladder cancer and lung cancer, but it is not associated with breast cancer [27–29]. The first study, published in 2002, revealed a borderline correlation between XPD Asp312Asn polymorphism and HNC risk in codominant model (for Asn/Asn vs. Asp/Asp: OR, 1.41; 95% CI: 1.01–1.97) [10]. To date, no consensus has been reached on the correlation between XPD Asp312Asn polymorphism and HNC risk. Majumder et al. [13] found that variant genotype (Asn/Asn) at codon 312 of XPD is associated with increased risk of bladder cancer and lung cancer, but it is not associated with breast cancer [27–29].

Figure 2. Sensitivity analysis through deletion of one study at a time to reflect the influence of the individual dataset to the pooled ORs in Asp/Asn vs. Asp/Asp model.
doi:10.1371/journal.pone.0035220.g002

Figure 3. Funnel plot analysis to detect publication bias for Asp/Asn vs. Asp/Asp genotype. Each point represents a separate study for the indicated association.
doi:10.1371/journal.pone.0035220.g003
cancer among rapid and intermediate acetylators (OR = 1.9, 95% CI = 1.2–2.9). However, other studies showed that HNC risk is not significantly related to XPD Asp312Asn polymorphism. Ji et al. [17] found that the OR of the Asp312Asn polymorphism genotype Asp/Asn is 1.94 (95% CI = 0.92–4.00) relative to the Asp/Asp genotype. Matullo et al. [11], An et al. [12], Harth et al. [14], Abbasi et al. [15], and Jelonek et al. [16] also reported similar risks of HNC.

The present meta-analysis of nine eligible studies, including 2670 cases and 4452 controls focused on XPD Asp312Asn polymorphism and HNC risk, was performed to derive a more precise estimate of the association, but no significant association was found in the total population when all the studies were pooled. Similarly, no significant association was detected in all genetic models during the satisfied analysis based on the HWE, ethnicity and study design. Our finding is not in accordance with that previously published by Flores-Obando et al [19]. A marginally significant association was observed between the XPD Asp312Asn heterozygous and combined variants and HNC in their study. The considerably larger sample size of our study may account for this difference relative to the previous study.

Despite the considerable efforts to test for possible association between XPD Asp312Asn polymorphism and HNC risk, some limitations should be addressed. First, these results are based on unadjusted estimates that lack the original data from the eligible studies, which limits the evaluation of the effects of the gene-gene and gene-environment interactions during HNC development. Second, the sample size is still relatively small. Thus, we could not have enough statistical data to find the true relationship between XPD Asp312Asn polymorphism and HNC risk. Finally, each gene is known to have a moderate effect on HNC development. The combinations of certain genotypes may be more discriminating as risk factors than a single locus genotype. In our meta-analysis, linkage disequilibrium (LD) and haplotype analysis were not performed. In spite of these limitations, no publication bias was observed, and a large number of subjects still significantly guarantee the statistical power of the analysis.

In conclusion, despite these limitations, our meta-analysis suggests that XPD Asp312Asn polymorphism may not be associated with HNC development. In the future, large-scale case-control and population-based association studies are necessary to validate the risks identified in the present meta-analysis and to investigate the potential gene-gene and gene-environment interactions between XPD Asp312Asn polymorphism and HNC cancer.

Supporting Information

Checklist S1 | PRISMA 2009 Checklist. (DOC)

Acknowledgments

We thank everyone who helped with this study.

Author Contributions

Conceived and designed the experiments: YYH HY YMN. Performed the experiments: YYH HY GRJ NC. Analyzed the data: LW WDL XTZ. Wrote the paper: YYH HY. Critical review of manuscript: YMN.

References

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137–2150.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371: 1695–1709.
3. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, et al. (1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48: 3292–3297.
4. Lichtenstein P, Holm NV, Verkasalo PK, Lilja A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78–85.
5. Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1513–1530.
6. Coint F, Marinoni KC, Rodolfo C, Fribourg S, Pedrini AM, et al. (1998) Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet 20: 184–188.
7. Winkler GS, Aranzo SJ, Fiedler U, Vermeulen W, Coint F, et al. (2000) TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair. J Biol Chem 275: 4258–4266.
8. de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogenesis 21: 453–460.
9. Pastorelli R, Cerri A, Mezzetti M, Consonni E, Airoldi L, et al. (2002) Effect of DNA repair gene polymorphisms on BPDE-DNA adducts in human lymphocytes. Int J Cancer 100: 9–13.
10. Sturig EM, Dahlstrom KR, Spitz MR, Wei Q (2002) DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otorhinolaryngol Head Neck Surg 128: 1084–1088.
11. Matullo G, Dunning AM, Guarerra S, Baynes C, Polidoro S, et al. (2006) DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 27: 1007–1010.
12. An J, Liu Z, Hu Z, Li G, Wang LE, et al. (2007) Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 16: 1633–1638.
13. Majumder M, Siklar N, Ghosh S, Roy B (2007) Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acylators. Int J Cancer 120: 2148–2156.
14. Harth V, Schafer M, Abel J, Maintz L, Neuhau s T, et al. (2008) Head and neck squamous-cell cancer and its association with polyomaviral enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 71: 897–897.
15. Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, et al. (2009) Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. Int J Cancer 125: 1431–1439.
16. Jelonek K, Gdowicz-Klosok A, Pietrowska M, Borkowska M, Kofanty J, et al. (2010) Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet 51: 343–352.
17. JYB, Tae K, Lee YS, Lee SH, Kim KR, et al. (2010) XPD Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck in a Korean Sample. Clin Exp Otorhinolaryngol 3: 42–47.
18. Gugatschka M, Dehelhamani D, Wascher TC, Friedrich G, Renner W (2011) DNA repair gene ERCC2 polymorphisms and risk of squamous cell carcinoma of the head and neck. Exp Mol Pathol 91: 331–334.
19. Flores-Obando RE, Gollin SM, Ragin CC (2010) Polymorphisms in DNA damage response genes and head and neck cancer risk. Biomarkers 15: 379–399.
20. Little J, Bradley L, Bray MS, Clyne M, Dormian J, et al. (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156: 300–310.
21. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820–826.
22. DeSimanison R, Laird N (1996) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
23. Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25: 3443–3457.
24. Wolfe KJ, Wiekifle JK, Hill CE, Padolina M, Aminounehem MM, et al. (2007) Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenom Genomics 17: 897–905.
25. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, et al. (2002) The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23: 599–603.
26. Matullo G, Palli D, Peluso M, Guarerra S, Curtasun S, et al. (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and 3292P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22: 1437–1445.
27. Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H (2010) Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys731Gln, in breast cancer. Breast Cancer Res Treat 124: 531–541.

28. Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH (2011) The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Med Oncol 28: 655–660.

29. Wang F, Chang D, Hu FL, Sui H, Han B, et al. (2008) DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev 17: 507–517.